---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-160703"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2024-06-13T23:59:59+00:00"
generated_at: "2026-06-01T04:38:53.178045+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# IN8bio Phase 1 INB-100 shows 100% durable CR at 1 year in leukemia patients

## Summary
- 100% of evaluable leukemia patients (n=10) remain in durable CR at 1 year as of May 31, 2024.
- First allogeneic cellular therapy to show in vivo gamma-delta T cell expansion/persistence at 365 days.
- Favorable safety: no DLTs, CRS, neurotoxicity, or ICANS observed.
- Two patients relapse-free >3.5 years; third nearing 3 years post-transplant.
- Trial expanded at Dose Level 2; FDA Type B meeting planned this summer for potential registrational path.

## SEC filing metadata
- accession: 0001193125-24-160703
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2024-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312524160703/0001193125-24-160703-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312524160703/d774911d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-160703
- JSON: https://secwatch.observer/filing/0001193125-24-160703.json
- Plain text: https://secwatch.observer/filing/0001193125-24-160703.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.